Carbamazepine (All indications)

Genital anomalies

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S9763
R34866		 Ban (Carbamazepine) (Mixed indications) (Controls exposed to Lamotrigine, sick), 2015 Genital system anomaly 1st trimester prospective cohort exposed to other treatment, sick excluded Adjustment: No 1.60 [0.14;17.69] C
excluded (control group) 		2/343   1/273 3 343
ref
S9764
R34872		 Ban (Carbamazepine) (Mixed indications) (Controls unexposed NOS), 2015 Genital system anomaly 1st trimester prospective cohort unexposed (general population or NOS) Adjustment: No 1.47 [0.37;5.90] C 2/343   1,023/257,153 1,025 343
ref
S9643
R34309		 Veiby (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 Genital throughout pregnancy population based cohort retrospective exposed to other treatment, sick Adjustment: No 1.83 [0.51;6.52] C 6/685   4/833 10 685
ref
S9652
R34351		 Artama (Carbamazepine), 2005 Genital organs 1st trimester retrospective cohort (registry) unexposed, sick Adjustment: No 0.93 [0.25;3.49] C 4/805   5/939 9 805
ref
Total 3 studies 1.37 [0.64;2.93] 1,044 1,833
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Ban (Carbamazepine) (Mixed indications) (Controls unexposed NOS), 2015Ban, 2015 1 1.47[0.37; 5.90]1,02534330%ROB confusion: criticalROB selection: moderateROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Veiby (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014Veiby, 2014 2 1.83[0.51; 6.52]1068536%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: moderateROB mesure: moderateROB reporting: moderate Artama (Carbamazepine), 2005Artama, 2005 3 0.93[0.25; 3.49]980534%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (3 studies) I2 = 0% 1.37[0.64; 2.93]1,0441,8330.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Carbamazepine) (Mixed indications) (Controls unexposed NOS; 2: Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications; 3: Carbamazepine;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.37[0.64; 2.93]1,0441,8330%NABan (Carbamazepine) (Mixed indications) (Controls unexposed NOS), 2015 Veiby (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 Artama (Carbamazepine), 2005 3 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.47[0.37; 5.90]1,025343 -NABan (Carbamazepine) (Mixed indications) (Controls unexposed NOS), 2015 1 unexposed, sickunexposed, sick 0.93[0.25; 3.49]9805 -NAArtama (Carbamazepine), 2005 1 exposed to other treatment, sickexposed to other treatment, sick 1.83[0.51; 6.52]10685 -NAVeiby (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 1 Tags Adjustment   - No  - No 1.37[0.64; 2.93]1,0441,8330%NABan (Carbamazepine) (Mixed indications) (Controls unexposed NOS), 2015 Veiby (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 Artama (Carbamazepine), 2005 3 All studiesAll studies 1.37[0.64; 2.93]1,0441,8330%NABan (Carbamazepine) (Mixed indications) (Controls unexposed NOS), 2015 Veiby (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 Artama (Carbamazepine), 2005 30.25.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 9763

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.47[0.37; 5.90]1,025343 -NABan (Carbamazepine) (Mixed indications) (Controls unexposed NOS), 2015 1 unexposed, sick controlsunexposed, sick controls 0.93[0.25; 3.49]9805 -NAArtama (Carbamazepine), 2005 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.78[0.58; 5.46]131,0280%NABan (Carbamazepine) (Mixed indications) (Controls exposed to Lamotrigine, sick), 2015 Veiby (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 20.510.01.0